Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair

Apr 20 2017

• By Jessica Merrill

Listen to this article

Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.

AirDuo RespiClick inhalers

Teva Pharmaceutical Industries Ltd. has taken the interesting step of launching AirDuo RespiClick (fluticasone/salmeterol) and an aggressively discounted authorized generic in the US on the same day. The company announced the availability of the two products April 20, both of which are formulated with the same active ingredients as GlaxoSmithKline PLC's AdvairDiskus, but are administered through a different device.

The authorized generic is priced at a steep discount to the AirDuo brand product – and to the leading brands...

More from Respiratory

Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa
Mar 10 2025
• By Andrew McConaghie
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Syros’s AML Failure Sparks MDS Program Jitters, But Fears May Be Overblown
Aug 14 2024
• By Alaric DeArment
Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.